Full Text View
Tabular View
No Study Results Posted
Related Studies
Deferoxamine for the Treatment of Hemochromatosis
This study has been completed.
Study NCT00001203   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: August 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus
Heart Disease
Hemochromatosis
Thalassemia
Additional conditions recognized in this trial
Heart Diseases
More general conditions related to this trial
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Cardiovascular Diseases
Endocrine System Diseases
Genetic Diseases, Inborn
Glucose Metabolism Disorders
Hematologic Diseases
Hemoglobinopathies
Iron Metabolism Disorders
Iron Overload
Metabolic Diseases
Metabolism, Inborn Errors
Metal Metabolism, Inborn Errors
Additional drug interventions recognized in this trial
Deferoxamine
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Siderophores
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services